Text Size
618 studies found for:    Erbitux

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab;   Drug: Cetuximab and Pemetrexed
2 Active, not recruiting Phase 1 and 2 Study of PX-866 and Cetuximab
Conditions: Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab;   Drug: Cetuximab
3 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
4 Completed An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasm
Intervention: Drug: Cetuximab
5 Completed Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: Cetuximab;   Procedure: Liver resection;   Drug: Cetuximab and FOLFIRI;   Drug: Cetuximab and FOLFOX
6 Completed
Has Results 		Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation therapy
7 Active, not recruiting Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
Condition: Cancer
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Cetuximab;   Procedure: Radiation Therapy
8 Active, not recruiting A Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab in combination with EMD 1201081;   Drug: Cetuximab alone
9 Active, not recruiting Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
Condition: Metastatic Colorectal Cancer
Interventions: Drug: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.;   Drug: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
10 Active, not recruiting Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
Condition: Cancer of Head and Neck
Interventions: Drug: Erbitux, Paclitaxel & Carboplatin;   Radiation: Radiation
11 Recruiting Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab;   Drug: Cetuximab
12 Recruiting A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment
Condition: Colorectal Neoplasms
Intervention: Drug: Erbitux (Cetuximab)
13 Active, not recruiting External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
14 Terminated EMMA-1 (Erbitux for Multiple Myeloma)
Condition: Multiple Myeloma
Intervention: Drug: Cetuximab +/- Dexamethasone
15 Completed Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Cetuximab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Cisplatin
16 Active, not recruiting Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: Cetuximab
17 Completed
Has Results 		Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
Condition: Pancreatic Cancer
Interventions: Drug: Cetuximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Capecitabine;   Radiation: Radiotherapy
18 Unknown † Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
Condition: Androgen-independent Prostate Cancer
Interventions: Drug: Erbitux (cetuximab) and Novantrone (mitoxantrone);   Drug: Novantrone (mitoxantrone)
19 Terminated Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Drug: Capecitabine;   Drug: Cetuximab;   Drug: Oxaliplatin
20 Recruiting Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Cetuximab
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years